KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Assets (2016 - 2025)

Pacira BioSciences has reported Assets over the past 16 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Assets at $1.3 billion for Q4 2025, down 18.58% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 18.58% YoY), and the annual figure for FY2025 was $1.3 billion, down 18.58%.
  • Assets for Q4 2025 was $1.3 billion at Pacira BioSciences, down from $1.3 billion in the prior quarter.
  • Over the last five years, Assets for PCRX hit a ceiling of $2.1 billion in Q4 2021 and a floor of $1.3 billion in Q4 2025.
  • Median Assets over the past 5 years was $1.5 billion (2023), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Assets: surged 62.83% in 2021 and later dropped 19.46% in 2023.
  • Pacira BioSciences' Assets stood at $2.1 billion in 2021, then fell by 18.99% to $1.7 billion in 2022, then decreased by 6.35% to $1.6 billion in 2023, then fell by 1.33% to $1.6 billion in 2024, then dropped by 18.58% to $1.3 billion in 2025.
  • The last three reported values for Assets were $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.